Biotech Startups
Quantum BioPharma Highlights Lucid-MS and unbuzzd Growth Potential in BioMedWire Podcast
Quantum BioPharma's co-founder discusses the unmet need in multiple sclerosis treatment with Lucid-MS and the commercial potential of unbuzzd, as the company prepares for a Phase 2 trial.
VERAXA Biotech Secures $27.5M Financing and $50M Equity Line Ahead of Planned Nasdaq Listing
VERAXA Biotech AG has obtained $27.5 million in convertible note financing and a $50 million equity line from two investment firms to bolster its financial position before a planned business combination and Nasdaq listing.
Lantern Pharma Raises $4.4 Million in Registered Direct Offering, Plans to Spin Out AI Platform
Lantern Pharma announced a $4.4 million registered direct offering and plans to create an independent entity for its AI platform, withZeta.ai, signaling a strategic shift to monetize its technology.
OS Therapies Advances Key Cancer Treatment Toward Regulatory Filings and Plans Animal Health Spin-off
OS Therapies Inc. is progressing its lead cancer drug OST-HER2 toward U.S. and U.K. regulatory submissions while planning to spin off its animal health division into a separate public company, potentially creating significant value for shareholders.
BioXgen Seeks Crowdfunding Investment for Cardiac Patch Targeting Post-Surgery Complication
BioXgen is launching a Regulation Crowdfunding investment round and hosting a webinar to demonstrate its cardiac patch designed to prevent postoperative atrial fibrillation, a common complication affecting nearly half of open-heart surgery patients.
Pelage Pharmaceuticals Raises $120 Million for Revolutionary Hair Growth Therapy
Pelage Pharmaceuticals secured $120 million in Series B funding to advance its novel regenerative hair growth therapy PP405, which could transform treatment for millions suffering from hair loss by reactivating dormant hair follicle stem cells.
FELIQS Secures $9 Million in Series A Funding to Advance Treatment for Retinopathy of Prematurity
FELIQS Corporation's $9 million Series A funding will accelerate the clinical development of FLQ-101, a promising treatment for retinopathy of prematurity, addressing a critical unmet need in neonatal care.
Unbuzzd Wellness Prepares for Potential IPO with New Auditor Appointment
Quantum BioPharma's portfolio company Unbuzzd Wellness Inc. has appointed MNP LLP as its new auditor and completed a name change, signaling strategic preparations for a potential public listing and capital raising efforts.